On This Day in Health: April 18, 2024
On April 18, 2024, the U.S. Food and Drug Administration approved alectinib, marketed as Alecensa, as an adjuvant treatment for selected patients with ALK-positive non-small cell lung cancer. Adjuvant treatment is given after surgery to reduce the chance that disease will return. The approval applied after tumor resection when tumors measured at least four centimeters or involved lymph nodes, with ALK positivity established through an FDA-approved test. It expanded the use of a targeted medicine into an earlier stage of care. The milestone was therefore about the setting and purpose of treatment, rather than the first discovery or first approval of alectinib itself.
ALK is a gene involved in cell signaling. In a subset of lung cancers, an alteration involving ALK helps drive abnormal growth. Alectinib inhibits the associated kinase activity, making the molecular feature of the tumor central to treatment selection. This relationship explains why a pathology diagnosis alone was insufficient for the new indication: laboratory testing had to establish the relevant target. The medicine had previously been used for advanced ALK-positive lung cancer. After surgery, the immediate clinical problem differs because the visible tumor has been removed, but microscopic disease may remain and lead to recurrence. An adjuvant trial asks whether treatment can improve outcomes in that particular situation.
The approval was supported by ALINA, a randomized trial involving 257 patients with completely resected ALK-positive disease. Investigators compared alectinib with platinum-based chemotherapy. The main measure was disease-free survival, reflecting recurrence or death rather than simply changes in the size of an existing tumor. The findings showed a substantial improvement in that measure with alectinib. The reported hazard ratio was approximately 0.24, corresponding to a reduction in the relative hazard of recurrence or death in the studied population. That combined endpoint should not be shortened into a claim that deaths alone fell by the same amount. Overall survival evidence was not mature enough to establish that conclusion at the time of approval.
April 18 illustrates how an established targeted therapy can take on a new role when a separate clinical trial supports it. Treatment after surgery brings its own balance of benefit, duration and adverse effects, including the need to monitor for liver problems and other serious reactions. A molecularly selected approach also depends on access to reliable tumor testing. The anniversary’s importance is the extension of precision treatment beyond the management of visible advanced disease and into the effort to prevent recurrence. It remains a specific advance for a defined group, supported by a defined outcome. Describing those boundaries preserves the meaning of the evidence and the distinction between a promising disease-free survival result and a proven effect on length of life.
The adjuvant alectinib approval occurred on April 18, 2024.
Eligibility required ALK-positive disease after tumor resection.
Tumor size or lymph-node involvement defined the approved setting.
The randomized ALINA trial enrolled 257 patients.
Disease-free survival improved compared with platinum chemotherapy.
The combined recurrence-or-death result was not proof of the same reduction in deaths alone.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.